On 1 January, 2017 Emmanuelle (Emma) Boishardy, previously the Rare Diseases Business Unit Head and Commercial Lead for the amyloidosis therapeutic area for France and the EU, became the new General Manager of GSK Pharmaceuticals. She replaces PharmDr. Monika Horníková, MHA who worked for GSK for almost 25 years.
Monika Horníková joined GSK in 1992 as a Medical Representative of the then Glaxo Československo company. Following the merger with SmithKline Beecham in 2001 she accepted the offer to become the General Manager of GSK Slovakia and later she also headed the Latvian and Estonian branch offices of the company. Since 2007 she was the General Manager of GSK Pharmaceuticals in the Czech Republic and also the CE Oncology HUB Lead. Under her leadership GSK regularly ranked among the best employers and TOP responsible companies. In 2014, GSK successfully completed an equal opportunities audit and among other things earned the title “Workplace of the Future”. For nearly ten years she also presided over the boards of local Associations of Innovative Pharmaceutical Industry in Slovakia and in the Czech Republic. She was elected the third most successful Czech businesswoman in 2015.
In her new role, Emma Boishardy is going to focus on efficient implementation of the Company’s European strategy in the Czech market and on improving the overall performance of the CE Cluster. She joined GSK in 1999 as the Serevent Product Manager. In France she was responsible for the launch of Seretide on the market, leading subsequently the entire group portfolio and acting as the Marketing Director for four years. Her other roles at GSK included positions such as the Second Line Sales Manager, Urology Marketing and Sales Director, Operational Excellence Director and Commercial Director, Speciality Care, or Rare Diseases Business Unit Head and Commercial Lead for the amyloidosis therapeutic area for France and the EU.